Connect with us
European Gaming Congress 2024

Artificial Intelligence

ESR1-Mutated Metastatic Breast Cancer Market to Climb Swiftly at a Significant CAGR During the Study Period (2019–2032) | DelveInsight

Published

on

<!– Name:DistributionId Value:8793377 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:742e8a86-4f56-4cb2-be9c-c487fbb56566 –>

New York, USA, March 22, 2023 (GLOBE NEWSWIRE) — ESR1-Mutated Metastatic Breast Cancer Market to Climb Swiftly at a Significant CAGR During the Study Period (2019–2032) | DelveInsight

The ESR1-mutated metastatic breast cancer market is expected to surge in the coming years due to the rising prevalence of metastatic breast cancer over the globe, which is increasing the probabilities of ESR1-mutated metastatic breast cancer and thus the surge in treatment options. Along with these, the expected launch of emerging therapies will boost the ESR1-mutated metastatic breast cancer market.

DelveInsight’s ESR1-Mutated Metastatic Breast Cancer Market Insights report includes a comprehensive understanding of current treatment practices, ESR1-mutated metastatic breast cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the ESR1-Mutated Metastatic Breast Cancer Market Report

Advertisement
  • As per DelveInsight analysis, the ESR1-mutated metastatic breast cancer market size in the 7MM was approximately USD 1.5 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total HR-positive breast cancer diagnosed prevalent cases in the 7MM was approximately 1.2 million in 2021. 
  • Leading ESR1-mutated metastatic breast cancer companies such as Radius Pharmaceuticals, Berlin-Chemie, Pfizer, G1 Therapeutics, Inc., Sun Pharma Advanced Research Company, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine, Eisai, Roche, AstraZeneca, Zentalis Pharmaceuticals, Olema Pharmaceuticals, and others are developing novel ESR1-mutated metastatic breast cancer drugs that can be available in the ESR1-mutated metastatic breast cancer market in the coming years.
  • The promising ESR1-mutated metastatic breast cancer therapies in the pipeline include Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), SCO-120, ZB716, ARV-471, Lasofoxifene, H3B-6545, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), ZN-c5, OP1250, and others.
  • On October 21, 2022, Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers specifically, presented additional findings from its Phase II Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1) study today at the 4th Annual Congress of the International Society of Liquid Biopsy (ISLB) in Miami.
  • On August 17, 2022, Sanofi discontinued the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD).
  • In August 2022, Zentalis announced that they discontinued the clinical development of ZN-c5, its oral SERD, and ZN-e4, its EGFRinhibitor, following completion of its existing clinical trials, which are closed to accrual, in these two programs.
  •  In August 2022, the FDA granted priority review to NDA seeking the approval of elacestrant for use in patients with estrogen receptor (ER)–positive/HER2-negative advanced or metastatic breast cancer. Under the Prescription Drug User Fee Act, the regulatory agency is expected to decide on the application by February 17, 2023.
  • In August 2022, FDA granted a fast-track designation to OP-1250 for the treatment of patients with ER-positive, HER2- metastatic breast cancer. 
  • In April 2022, Roche announced the first-quarter result and stated that giredestrant missed the mark in the Phase II acelERA trial in advanced breast cancer, the emerging oral selective estrogen receptor degrader (SERD) class. 

Discover which therapies are expected to grab the major ESR1-mutated metastatic breast cancer market share @ ESR1-Mutated Metastatic Breast Cancer Market Report

ESR1-Mutated Metastatic Breast Cancer Overview

Metastatic breast cancer is essentially a Stage IV breast cancer in which cancer begins in the breast tissue and then spreads to other parts of the body. Estradiol, a steroid hormone, is important in the progression of breast cancer, and the majority of human breast cancers begin as estrogen-dependent and express the estrogen receptor (ER). ESR1 mutations are more commonly selected in cancers that progress after sensitivity to prior aromatase inhibitor therapy and are relatively rare in patients with intrinsic endocrine resistance.

ESR1 mutations rarely occur in primary breast cancer but are common in advanced breast cancers previously treated with aromatase inhibitors, implying evolution through selective treatment pressure. Most ESR1 mutations occur in hotspot regions of the ER’s ligand-binding domain, resulting in ligand-independent, constitutive ER activity.

Tumor tissue and baseline liquid biopsies could be used for mutation detection using sensitive next-generation sequencing (MPS) at the time of diagnosis. Following neoadjuvant therapy, Droplet Digital PCR ddPCR could be used to confirm ESR1 mutations.

ESR1-Mutated Metastatic Breast Cancer Epidemiology Segmentation

Advertisement

DelveInsight estimates that there were approximately 1.2 million HR-positive breast cancer diagnosed prevalent cases in the 7MM in 2021.

Among the EU-4 and the UK countries, Germany captured the highest diagnosed prevalent cases of ESR1 mutated metastatic breast cancer in 2021.

The ESR1-mutated metastatic breast cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Diagnosed Prevalent Cases of HR-Positive Breast Cancer
  • Stage-specific Diagnosed Prevalent Cases of HR-positive Breast Cancer
  • Total Diagnosed Prevalent Cases of Metastatic Breast Cancer
  • Diagnosed Prevalent Cases of ESR1 Mutated Metastatic Breast Cancer
  • Line-wise treatable cases of ESR1 Mutated Metastatic Breast Cancer

Download the report to understand which factors are driving ESR1-mutated metastatic breast cancer epidemiology trends @ ESR1-Mutated Metastatic Breast Cancer Epidemiological Insights

ESR1-Mutated Metastatic Breast Cancer Treatment Market 

Patients with ESR1 mutations benefit clinically from fulvestrant and CDK4/6 targeted therapies, but more potent selective estrogen receptor degraders (SERDs) and new targeted biotherapies are needed to overcome the endocrine-resistant phenotype of ESR1 mutant-bearing tumors. There are effective ETs for treating patients with ER-positive metastatic disease. Rather than sequencing single endocrine agents, ET and biotherapy combinations are now commonly used to treat ET-resistant MBC. For ER-positive breast cancer, two biological targets have been approved: mammalian target of rapamycin (mTOR) and cyclin-dependent kinases (CDK) 4/6. 

Advertisement

According to ESR1-mutated metastatic breast cancer treatment guidelines, patients who develop MBC 12 months after adjuvant ET or who are newly metastatic should be treated in the first-line setting with an AI combined with a CDK4/6 inhibitor.

Although many preclinical studies have shown that ESR1 mutant cells respond to fulvestrant with less sensitivity, recent retrospective analyses of the PALOMA-2 clinical trial published by O’Leary et al. revealed that patients treated with fulvestrant monotherapy alone or in combination with palbociclib continued to acquire the Y537S ESR1 mutation during treatment.

Furthermore, a more recent retrospective correlative analysis of the PALMOA-3 trial investigated whether early changes in ESR1 or PIK3CA mutations measured using ddPCR of ctDNA were predictive of therapy response. Although total ESR1 mutant abundance decreased in both treatment arms, these changes were not predictive of fulvestrant response.

To know more about ESR1-mutated metastatic breast cancer treatment, visit @ ESR1-Mutated Metastatic Breast Cancer Treatment Drugs 

ESR1-Mutated Metastatic Breast Cancer Pipeline Therapies and Key Companies

Advertisement
  • Elacestrant (RAD1901): Radius Pharmaceuticals/Berlin-Chemie (Menarini Group)
  • Ibrance (Palbociclib): Pfizer
  • Rintodestrant (G1T48): G1 Therapeutics, Inc.
  • SCO-120: Sun Pharma Advanced Research Company
  • ZB716: Zenopharm
  • ARV-471: Arvinas
  • Lasofoxifene: Sermonix Pharmaceuticals
  • H3B-6545: H3 Biomedicine/Eisai
  • Giredestrant (RG6171, GDC-9545): Roche
  • Camizestrant (AZD9833): AstraZeneca
  • ZN-c5: Zentalis Pharmaceuticals
  • OP1250: Olema Pharmaceuticals

Learn more about the FDA-approved drugs for ESR1-mutated metastatic breast cancer @ Drugs for ESR1-Mutated Metastatic Breast Cancer Treatment 

ESR1-Mutated Metastatic Breast Cancer Market Dynamics

The ESR1-mutated metastatic breast cancer is expected to boost in the coming years due to the rising global incidence of ER+ breast cancer, combined with an increase in the use of endocrine drugs, will contribute to an increase in the incidence of ESR1 mutant breast cancer and, as a result, a surge in treatment options. Moreover, the increase in clinical trial activity for emerging therapies will drive the ESR1-mutated metastatic breast cancer market forward.

In addition, a lack of approved and effective therapies may provide good ESR1-mutated metastatic breast cancer market space for emerging therapies. Furthermore, the rising disease awareness among researchers, clinicians, and patients will drive the ESR1-mutated metastatic breast cancer market size.

Moreover, the current unmet need of the ESR1 mutant breast cancer market is for medications with improved safety and effectiveness that provide the best cure. There is a need to concentrate on therapies with higher compliance in the ESR1 mutant breast cancer market.

However, a lack of comprehension of the occurrence and clinical significance may represent a missed ESR1 mutant breast cancer market opportunity to make the correct diagnosis. Current pharmacological therapies have limitations, such as limited activity. Furthermore, the drugs are sometimes the root cause of this specific mutation in patients.

Advertisement

The current treatments, such as CDK4/6 inhibitors, are prohibitively expensive. As this mutation was discovered only a decade ago, there is very little data available in studies, and thus very little work has been done to date. Furthermore, strict pricing and reimbursement policies will significantly challenge the ESR1 mutant breast cancer market growth. Another major cause of unsatisfactory current patient care is a lack of awareness, which may impede ESR1 mutated breast cancer market growth.

Report Metrics Details
Study Period 2019–2032
Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year 2019
ESR1-Mutated Metastatic Breast Cancer Market Size in 2021 USD 1.5 Billion
Key ESR1-Mutated Metastatic Breast Cancer Companies Radius Pharmaceuticals, Berlin-Chemie, Pfizer, G1 Therapeutics, Inc., Sun Pharma Advanced Research Company, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine, Eisai, Roche, AstraZeneca, Zentalis Pharmaceuticals, Olema Pharmaceuticals, and others
Key Pipeline ESR1-Mutated Metastatic Breast Cancer Therapies Elacestrant (RAD1901), Ibrance (Palbociclib), Rintodestrant (G1T48), SCO-120, ZB716, ARV-471, Lasofoxifene, H3B-6545, Giredestrant (RG6171, GDC-9545), Camizestrant (AZD9833), ZN-c5, OP1250, and others

Scope of the ESR1-Mutated Metastatic Breast Cancer Market Report

  • Therapeutic Assessment: ESR1-Mutated Metastatic Breast Cancer current marketed and emerging therapies
  • ESR1-Mutated Metastatic Breast Cancer Market Dynamics: Attribute Analysis of Emerging ESR1-Mutated Metastatic Breast Cancer Drugs 
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, ESR1-Mutated Metastatic Breast Cancer Market Access and Reimbursement

Discover more about ESR1-mutated metastatic breast cancer drugs in development @ ESR1-Mutated Metastatic Breast Cancer Clinical Trials

Table of Contents

1. ESR1-Mutated Metastatic Breast Cancer Market Key Insights
2. ESR1-Mutated Metastatic Breast Cancer Market Report Introduction
3. ESR1-Mutated Metastatic Breast Cancer Market Overview at a Glance
4. ESR1-Mutated Metastatic Breast Cancer Market Executive Summary
5. Disease Background and Overview
6. ESR1-Mutated Metastatic Breast Cancer Treatment and Management
7. ESR1-Mutated Metastatic Breast Cancer Epidemiology and Patient Population
8. Patient Journey
9. ESR1-Mutated Metastatic Breast Cancer Marketed Drugs
10. ESR1-Mutated Metastatic Breast Cancer Emerging Drugs
11. Seven Major ESR1-Mutated Metastatic Breast Cancer Market Analysis
12. ESR1-Mutated Metastatic Breast Cancer Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. ESR1-Mutated Metastatic Breast Cancer Market Drivers
16. ESR1-Mutated Metastatic Breast Cancer Market Barriers
17. Unmet Needs
18. SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Related Reports

ESR1-Mutated Metastatic Breast Cancer Epidemiology Forecast

Advertisement

ESR1-Mutated Metastatic Breast Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted ESR1-mutated metastatic breast cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

ESR1-Mutated Metastatic Breast Cancer Pipeline

ESR1-Mutated Metastatic Breast Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ESR1-mutated metastatic breast cancer companies, including Radius Pharmaceuticals, Berlin-Chemie, Pfizer, G1 Therapeutics, Inc., Sun Pharma Advanced Research Company, Zenopharm, Arvinas, Sermonix Pharmaceuticals, H3 Biomedicine, among others.

HER2-Positive Breast Cancer Market

HER2-Positive Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2-positive breast cancer companies, including Shanghai Henlius Biotech, Roche Pharma AG, GeneQuantum Healthcare (Suzhou) Co., Ltd., Klus Pharma Inc., Carisma Therapeutics Inc, among others.

Advertisement

HER2-Positive Early Breast Cancer Pipeline

HER2-Positive Early Breast Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2-positive early breast cancer companies, including Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, DualityBio Inc., Seagen Inc., among others.

HER2-Positive Early Breast Cancer Market

HER2-Positive Early Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2-positive early breast cancer companies, including Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, DualityBio Inc., Seagen Inc., among others.

HER2-Negative Breast Cancer Market

Advertisement

HER2-Negative Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2-negative breast cancer companies, including Sanofi, BeiGene, AstraZeneca, Radius Pharmaceuticals, Novartis, Amgen, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Blogs

Upcoming Oncological Drugs in 2023

Advertisement

Metastatic Castration-Sensitive Prostate Cancer Treatment Market

Checkpoint Inhibitor Refractory Cancer Market

Promising Oncolytic Virues Candidates in Pipeline

ENHERTU’s Journey in Cancer Treatment and Management

Potential of PD-1 and PD-L1 Inhibitors in Cancer Management

Advertisement

Evolving EGFR NSCLC Treatment Market Dynamics

Emerging Role of Digital Health in the Field of Oncology

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Advertisement

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter


Advertisement

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Huawei Wen Tong: 6G Needs to Embrace AI for Shaping Future Network

Published

on

huawei-wen-tong:-6g-needs-to-embrace-ai-for-shaping-future-network

SHENZHEN, China, Sept. 29, 2024 /PRNewswire/ — At the 6G Conference held in Istanbul, on September 24, 2024, Dr. Wen Tong, Huawei Wireless CTO, delivered a keynote speech on 6G standardization and innovation. With the release of the ITU-R 6G vision framework, the 3GPP will start 6G standardization in 2025. “6G is a new generation of mobile technology, not a simple upgrade of 5G, it should bring new value to users,” said Dr. Tong, “6G is a true intergenerational technological disruption. 6G standard, key technologies, and network architecture should be re-defined based on application scenarios and requirements from 2030 to 2040. 6G should not be another way to implement 5G. Instead, 6G should embrace the AI revolution with a quantum leap and generate new values for the consumers. In this way, 3GPP standards can truly realize the 6G vision and create greater value for the entire industry.”

Centered “6G Standardization Direction” and “6G Innovation Driving Force”, Dr. Tong shared important views on the future architecture, terminal development, and key technologies of 6G.
In terms of architecture design, 6G should go beyond Service-Based Architecture and move towards Application-Driven Network.
5G has already achieved market success and continues to evolve towards 5G-Advanced. 6G will not simply reuse 5G network architecture, without generational and fundamental innovations, which will limit the mobile industry’s aspiration and imagination to dive the innovation in the 6G era. 6G must have obvious cross-generational characteristics and technical breakpoint.
On the core side, reusing the 5G core network will hinder the innovation in AI. We should use Agentic-AI based technology to re-architect 6G Core that goes beyond 5G Service-Based Architecture and support the foundational capabilities of AI, Sensing and NTN , and thus evolve towards the Application Driven Network .
In terms of terminal evolution, 6G user device calls for a breakthrough to lead the success of the entire industry chain.
It is the law of the mobile industry to drive the evolution of the market with the pioneering technology. The 6G networks and 6G terminals must meet the requirements of consumers and vertical industries in the 6G market phase from 2030 to 2040.
Currently, smartphones are evolving to AI terminals to usher in the mobile AI era. In post-MBB era, breakthroughs in terminal technologies will be the key to the evolution of the mobile industry. Therefore, 6G user device calls for a breakthrough towards “Full-AI”, thus to drive 6G network upgrade and the success of the entire industry ecosystem.
In terms of technology development, AI will become a key enabler for 6G with network paradigm shifting.
Twenty years ago, the Internet was the enabler of the technology innovations. Mobile communications embraced the Internet and achieved great business success. Today, AI maybe the disruptive enabler of the latest technology innovations.
6G should embrace the AI revolution with a quantum leap. However, 6G networks should not be limited to generative AI, Artificial General Intelligence (AGI) and Embodiment-AI are the main directions of future AI development. Therefore, AGI should run through the whole process of sensing, reasoning, decision, and action of terminals, wireless networks, and core networks of 6G, to welcome the arrival of a new network paradigm.
At the end, Dr. Tong Wen emphasized the relationship between 5G and 6G: “The global 5G deployment is on the rise and evolving to 5G-Advanced, which not only meets the current requirements of operators, but also protects their investment. Therefore, 6G technologies should not overlap with 5G in technologies and market space. The specifications, technologies, and architecture of 6G must be based on the scenarios and requirements from 2030 to 2040. We should focus on true generational technology disruption, embrace the new opportunities brought by AI, expand the mobile industry in the next generation.”
Photo – https://mma.prnewswire.com/media/2518236/Huawei_Wireless_CTO_Tong_Wen_Gave_Keynote_Speech_at_6G_Conference_at_Istanbul__T_rkiye.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/huawei-wen-tong-6g-needs-to-embrace-ai-for-shaping-future-network-302261758.html

Continue Reading

Artificial Intelligence

How AIoT shapes the future of mobility: Hikvision at ITS World Congress 2024

Published

on

how-aiot-shapes-the-future-of-mobility:-hikvision-at-its-world-congress-2024

HANGZHOU, China, Sept. 27, 2024 /PRNewswire/ — Hikvision made a significant impact at the ITS World Congress in Dubai with its captivating theme, “Embrace AIoT for safer, smarter, and greener mobility.” Its booth became a hub of innovation, where visitors explored AIoT solutions that are reshaping the transportation landscape, sparking deep conversations on the future of urban mobility.

Road safety revolution: harnessing AIoT for secure transportation
Hikvision’s commitment to road safety was on full display at its booth through the impressive array of AIoT solutions designed to create secure and reliable traffic environments. The company’s technology provides 24/7 traffic monitoring, ensuring continuous oversight of motor vehicles, non-motorized vehicles, pedestrians and environmental factors. This comprehensive, real-time information collection enables traffic managers to prevent accidents and enhance road safety. Among the showcased products was the 20 MP IR ANPR Checkpoint Capture Unit, renowned for its high-definition capture capabilities, bolstering traffic safety measures.
A standout innovation was the integration of advanced radar and camera technologies, ensuring uninterrupted, comprehensive detection even in adverse weather conditions. The Radar-Video Fusion Incident Detection Cameras, featured prominently in the product experience area, enable early detection and warning of potential hazards. They are particularly effective in challenging situations such as curved roads, blind spots at intersections, and obstacles beyond visual range.
Attendees also engaged with onboard monitoring products on the simulated bus, including dome network cameras, which is designed to enhance passenger safety. Driving assistance products, such as the Driver Status Monitor (DSM), were demonstrated to mitigate unsafe driving behaviors and ensure safer journeys.
Urban mobility redefined: smart traffic innovations
In the realm of smarter mobility, Hikvision showcased its multidimensional sensing technology, which integrates visible light sensors, infrared sensors, radar, and sonar. This technology expands perception capabilities, significantly improving traffic management and situational awareness. The use of AI-powered comprehensive sensing elevates incident monitoring and violation detection to unprecedented levels of accuracy and efficiency.
A major attraction was the Radar-Video Fusion TandemVu PTZ Camera, which integrates millimeter-wave radar with high-resolution cameras for extensive traffic detection and data analysis. AI-based algorithms combine these two systems to enhance target information, detecting up to 16 types of incidents. This leads to the development of a large-scale fusion model that merges spatial physical data with image semantic information. The result is ultra-long-range perception, achieving over 95% accuracy in vehicle trajectory detection. This robust system improves traffic violation management and optimizes traffic flow, significantly enhancing road efficiency.
At the simulated bus station, visitors observed how AI-assisted people counting automated the collection of passenger flow statistics at peak stop hours and bus line frequency during busy periods. Paired with smart bus stop digital signage, the solution improves bus service quality, operational efficiency, passenger experience, and overall public transport effectiveness.
Sustainable transportation: leading the charge for greener cities
Hikvision’s commitment to sustainable urban mobility was evident through its innovative green wave technology and eco-friendly checkpoint solutions. Green wave technology efficiently manages traffic flow to reduce congestion and lower carbon emissions, aligning with global sustainability goals. Visitors were particularly impressed by a case study showcasing a green wave solution implemented in Zhoushan, China. Over a stretch of 21 kilometers and 34 intersections, this main road cut travel times by 50%.
The use of DarkFighterX technology in checkpoint cameras also received significant attention. This technology senses both visible and invisible light, resulting in more accurate and realistic images. It enhances traffic violation enforcement efficiency while minimizing the need for high ambient light levels, thus reducing light pollution. The 9M DarkfightX ANPR Checkpoint Camera exemplified this dedication to environmental stewardship.
Frank Zhang, President of Hikvision MEA, remarked, “Hikvision supports sustainable urban planning by empowering traffic departments to address congestion and transportation challenges.” He further emphasized, “Our system’s openness fosters a secure and reliable platform for developing smart and green cities. Additionally, our solar technology is extensively utilized in remote areas, while our smart street lighting solutions reduce energy consumption by 20-30%, promoting intelligent urban transportation and advancing global sustainability objectives.”
Hikvision’s presence at the ITS World Congress in Dubai underscored its leadership in integrating AIoT technologies to drive safer, smarter, and greener mobility solutions. The engaging presentations and advanced product demonstrations captured significant attention from industry partners and customers, reaffirming the company’s role as a pioneer in shaping the future of urban transportation. As the world moves towards more intelligent and sustainable transportation systems, Hikvision remains at the forefront, embracing AIoT to create a safer, smarter, and greener future for all.
To find out more about Hikvision’s advanced traffic and public transport solutions, please explore the Hikvision official website.
Photo – https://mma.prnewswire.com/media/2516934/How_AIoT_shapes_future_mobility_Hikvision_ITS_World_Congress_2024.jpg

View original content:https://www.prnewswire.co.uk/news-releases/how-aiot-shapes-the-future-of-mobility-hikvision-at-its-world-congress-2024-302261298.html

Continue Reading

Artificial Intelligence

Anti-Drone Market worth $7.05 billion by 2029 – Exclusive Report by MarketsandMarkets™

Published

on

anti-drone-market-worth-$7.05-billion-by-2029-–-exclusive-report-by-marketsandmarkets™

DELRAY BEACH, Fla., Sept. 27, 2024 /PRNewswire/ — The global anti-drone market was valued at USD 2.16 billion in 2024 and is projected to reach USD 7.05 billion by 2029; it is expected to register a CAGR of 26.7% during the forecast period according to a new report by MarketsandMarkets™. Increasing government spending on counter-drone technologies, rising incidence of critical infrastructure security breaches by unauthorized drones, and surge in adoption of aerial remote sensing technologies to safeguard critical infrastructure are attributed to the demand for anti-drone.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=177013645
Browse in-depth TOC on “Anti-Drone Market” 178 – Tables61 – Figures253 – Pages
Anti-Drone Market Report Scope:
Report Coverage
Details
Market Revenue in 2024
$ 2.16 billion
Estimated Value by 2029
$ 7.05 billion
Growth Rate
Poised to grow at a CAGR of 26.7%
Market Size Available for
2020–2029
Forecast Period
2024–2029
Forecast Units
Value (USD Million/Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
By System Type, Application, Platform type, Vertical, and Region
Geographies Covered
North America, Europe, Asia Pacific, and Rest of World
Key Market Challenge
Vulnerability to hacking
Key Market Opportunities
Emphasis on improving unmanned aircraft systems technology
Key Market Drivers
Growing number of illicit activities
By System Type: Hybrid systems to account for the larger market share in the forecasted year.
The hybrid segment accounted for the largest share of the anti-drone market in 2029. The trends of integrating multiple anti-drone technologies are rising since they are most effective in detecting, tracking, and neutralizing drone threats. These systems merge electronic, kinetic, and lasers, providing a comprehensive defense solution against UAVs. Hybrid systems use electronic, kinetic, and laser-based countermeasures to offer optimum protection against drones. These systems are designed to detect, track, identify, categorize, and mitigate drones at operational wide ranges ranging from a few km up to tens of km.
By Platform: The ground-based segment accounted for the largest market share in the forecast year.
The ground-based segment will hold a major share of the anti-drone market in 2029. Many ground-based anti-drone systems use several electronic technologies, such as radar, IR sensors, acoustic systems, and RF & GNSS jammers. MESA radar solutions are used mostly for counter-UAS purposes, protecting critical infrastructure, military camps, and other security-sensitive sites from unauthorized drones. One such solution is EchoGuard, a ground-based airspace management solution that contains a software-defined 3D radar that can be specific to the site. This system can identify single or multiple off-chance drones, including swarms in unauthorized areas. They provide accurate and sustained airspace surveillance for the field of view (FOV) they are configured, and both human and AI-monitored visual checks. The system can be easily transported and integrated directly with the command-and-control centers or another identification sensor for portable use, and multiple units of the system can be combined to cover vast areas or lengths of borders. Major providers of ground-based counter-drone systems include companies like EchoDyne Corporation, DeTect, Meteksan Defense, and WhiteFox Defense. Acoustics-based Discovair G2 utilizes patented microphone arrays. With 128 interconnected microphone elements, the Discovair sensor units can establish azimuth and elevation to the target in real-time using advanced digital signal processing.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=177013645
By Region: Americas are expected to hold the largest share of the anti-drone market during the forecast period.
Americas is expected to capture the largest share in the anti-drone industry during the forecast period. The growth can be attributed to protecting crucial infrastructure in the region. Governments, particularly in the US, invest in anti-drone systems for military bases, borders, and critical infrastructure. For Instance, in April 2023, RTX secured a USD 237 million contract from the US Army to provide Ku-band Radio Frequency Sensors (KuRFS) and Coyote effectors. These systems are designed to detect and neutralize unmanned aircraft systems (UAS). The contract includes stationary and mobile systems and a specified quantity of effectors, all aimed at enhancing the Army’s operations within the US Central Command region.
Key Players-
The key companies offering anti-drone companies include RTX (US), Lockheed Martin Corporation (US), Leonardo S.p.A. (Italy), Thales (France), and IAI (Israel).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=177013645
Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting
Related Reports: 
Drone Sensor Market Size, Share, Industry Growth & Trends by Sensor Type, Platform (VTOL Type, Fixed Wing Type, Hybrid Type), Application (Navigation, Collision Detection & Avoidance, Data Acquisition, Motion Detection, Power Monitoring), End Users and Region – Global Forecast to 2029
Smart Agriculture Market Size, Share, Statistics and Industry Growth Analysis Report by Offering (Hardware, Software, Services), Agriculture Type, Farm Size (Large, Medium, Small), Application (Precision Farming, Livestock Monitoring) and Region (America, Europe, Asia Pacific, Row) – Global Forecast to 2028
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact: Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected] Our Web Site: https://www.marketsandmarkets.com/Research Insight: https://www.marketsandmarkets.com/ResearchInsight/anti-drone-market.aspContent Source: https://www.marketsandmarkets.com/PressReleases/anti-drone.asp
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/anti-drone-market-worth-7-05-billion-by-2029—exclusive-report-by-marketsandmarkets-302260893.html

Continue Reading

Trending